Nicht-alkoholische Steatohepatitis: Epidemiologie, Diagnose und Therapie

Summary

Nonalcoholic steatohepatitis (NASH) is an hepatic disorder with histologic features of alcohol-induced liver diseases. NASH is believed to be one of the most common explanations for abnormal liver function tests and cryptogenic cirrhosis. Risk factors for NASH include obesity, type II diabetes, hyperlipidemia, total parenteral nutrition and the use of certain medications. Most affected individuals are clinically asymptomatic and the gold standard in diagnosis is liver biopsy. The latter also provides important information as a prognositic parameter since patients with steatohepatitis, necrosis, or cirrhosis develop clinically significant complications of liver disease. The pathophysiology of NASH is incompletely understood; recent animal models such as the ob/ob mouse (deficient leptin synthesis) have brought significant insight into the link of metabolic disorders with inflammation. These models should give important clues how to treat these disorders in the future as currently there are no accepted therapies for the treatment of NASH and prevention of clinically relevant liver disease.

Literatur

• 1 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 2 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
• 3 Brunt E M, Janney C G, DiBisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94 2467-2474
• 4 Caldwell S H, Oelsner D H, Iezzoni J C, Hespenheide E E, Battle E H, Driscoll C J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.  Hepatology. 1999;  29 664-669
• 5 Cello J P, Grendell J H. The liver in systemic conditions. Philadelphia, W.B. Saunders In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease 1990: 1428-1429
• 6 Cortez-Pinto H, Chatham J, Chacko V P, Arnold C, Diehl A M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study.  JAMA. 1999;  282 1659-1664
• 7 Fletcher L M, Kwoh-Gain I, Powell E E, Powell L W, Halliday J W. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis.  Hepatology. 1991;  13 455-459
• 8 Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin M F, Surwit R S, Ricquier D, Warden C H. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulenemia.  Nat Genet. 1997;  15 269-272
• 9 George D K, Goldwurm S, Macdonald G A, Cowley I L, Walker N I, Ward P J, Jazwinska E C, Powell L W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology. 1998;  114 311-318
• 10 Kim W, Poterucha J J, Porayko M K, Dickson E R, Steers J L. Recurrence of nonalcoholic steatohepatitis following liver transplantation.  Tranplantation. 1996;  62 1802-1805
• 11 Lin H Z, Yang S Q, Chuckaree C, Kuhajda F, Ronnet G, Diehl A M. Metformin reverses fatty liver diseasee in obese, leptin-deficient mice.  Nat Med. 2000;  6 998-1003
• 12 Lipsky P E, van der Heijde D, Clair E W, Furst D E, Breedveld F C, Kalden J R, Smolen J S, Weisman M, Emery P, Feldmann M, Harrimann G R, Maini R N. Infliximab and methotrexate in the treatment of rheumatoid arthritis.  N Engl J Med. 2000;  343 1594-1602
• 13 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
• 14 Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116 1413-1419
• 15 McFarland R J, Gazet J C, Pilkington T R. A 13-year review of jejunoileal bypass.  Br J Surg. 1985;  72 81-87
• 16 Mendler M -H, Turlin B, Moirand R, Jouanolle A -M, Sapey T, Guyader D, Le Gall J -Y, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload.  Gastroenterology. 1999;  117 1155-1163
• 17 Miglio F, Rovati L C, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group placebo-controlled prospective clinical study.  Arzneimittelforschung. 2000;  50 722-727
• 18 Pelleymounter M A, Cullen M J, Baker M B, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice.  Science. 1995;  269 540-543
• 19 Phillips M S, Liu Q, Hammond H A, Dugan V, Hey P J, Caskey C J, Hess J F. Leptin receptor missense mutation in the fatty Zucker rat.  Nat Genet. 1996;  13 18-19
• 20 Poonawala A, Nair S P, Thuluvath P J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study.  Hepatology. 2000;  32 689-692
• 21 Powell E E, Cooksley W G, Hanson R, Searle J, Halliday J W, Powell L W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.  Hepatology. 1990;  11 74-80
• 22 Sheth S G, Gordon F D, Chopra S. Nonalcoholic steatohepatitis.  Ann Intern Med. 1997;  126 137-145
• 23 Shulman G I. Cellular mechanisms of insulin resistance in humans.  Am J Cardiol. 1999;  84 3J-10J
• 24 Targan S R, Hanauer S B, van Deventer S J, Mayer L, Present D H, Braakman T, DeWoody K L, Schaible T F, Rutgeerts P J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn¿s disease.  N Engl J Med. 1997;  337 1029-1035
• 25 Tilg H, Diehl A M. Cytokines in alcoholic and nonalcoholic steatohepatitis.  N Engl J Med. 2000;  343 1467-1476
• 26 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110

Korrespondenz